GO:0009437 carnitine metabolic process explained

Carnitine metabolic process (GO:0009437) is a biological process defined as the chemical reactions and pathways involving carnitine (hydroxy-trimethyl aminobutyric acid), a compound that participates in the transfer of acyl groups across the inner mitochondrial membrane. Carnitine is a small, water-soluble molecule that is obtained from diet and synthesized endogenously, and it is best known for its obligatory role in mitochondrial fatty acid oxidation. The process encompasses carnitine biosynthesis, transport, acylcarnitine formation, and the reversible exchange of acylcarnitine species across mitochondrial membranes. Researchers study this term because carnitine metabolism sits at the intersection of energy homeostasis, lipid handling, and cellular stress responses, and its dysfunction is implicated in a wide range of human diseases. The carnitine system is not a single enzyme but a coordinated network of transporters and enzymes that maintain the balance between free carnitine and acylcarnitine pools. In muscle and heart, carnitine supports high rates of fatty acid oxidation for ATP production, and supplementation has been investigated for exercise performance and cardiac function. Inborn errors affecting carnitine transport or acylcarnitine shuttle components cause severe metabolic presentations, including cardiomyopathy and hypoketotic hypoglycemia. Beyond inherited disorders, acquired alterations in carnitine metabolism have been detected in inflammatory skin disease and ischemic stroke, where specific acylcarnitine species correlate with disease severity. Because carnitine metabolic process is both mechanistically central and clinically relevant, it is a productive area for functional genomics. Modern CRISPR-based models allow researchers to delete, mutate, or overexpress individual components and measure the consequences for fatty acid oxidation, acylcarnitine profiles, and disease phenotypes. This article summarizes the authoritative definition, the core biochemical steps, the key genes, and the experimental methods used to study GO:0009437.

In simple terms, GO:0009437 carnitine metabolic process covers all the chemical reactions and pathways that make, use, transport, and modify carnitine in a cell. The official definition states that it is the chemical reactions and pathways involving carnitine (hydroxy-trimethyl aminobutyric acid), a compound that participates in the transfer of acyl groups across the inner mitochondrial membrane. This includes carnitine biosynthesis from protein-derived trimethyllysine, uptake of carnitine by specific transporters, formation of acylcarnitine esters by carnitine acyltransferases, and the exchange of acylcarnitines across the inner mitochondrial membrane. The term is a biological process in the Gene Ontology, and its synonyms include carnitine metabolism, vitamin Bt metabolic process, and vitamin Bt metabolism.

Carnitine metabolic process is fundamentally important because it enables the mitochondrial import of long-chain fatty acids, which is required for energy production in tissues such as heart and skeletal muscle. Without functional carnitine metabolism, cells cannot efficiently oxidize fatty acids, leading to energy failure and accumulation of toxic acylcarnitine intermediates. The process also buffers acyl-CoA pools and influences substrate selection between glucose and fat, making it a key node in metabolic regulation. Clinically, defects in carnitine transport or the carnitine shuttle cause severe inherited disorders, and acquired changes in carnitine and acylcarnitine levels are associated with inflammatory and ischemic diseases. Consequently, carnitine metabolic process is a high-value target for mechanistic studies, biomarker discovery, and therapeutic development.

The following genes and proteins are central to carnitine metabolic process, covering biosynthesis, transport, acylcarnitine formation, and mitochondrial exchange.

Carnitine metabolic process is regulated at multiple levels. Transcriptional control of fatty acid oxidation genes, including CPT1A and CPT1B, is mediated by nuclear receptors such as PPARA and coactivators like PPARGC1A, which adjust mitochondrial oxidative capacity in response to energy demand. The activity of CPT1 is inhibited by malonyl-CoA, linking carnitine-dependent fatty acid oxidation to glucose availability and insulin signaling. Carnitine transport via SLC22A5 is regulated by substrate availability and hormonal signals, and carnitine biosynthesis is controlled by enzyme expression in liver and kidney. In cancer, metabolic reprogramming can alter PGC1alpha-dependent mitochondrial function, indirectly affecting carnitine-dependent pathways. Additionally, acylcarnitine levels reflect the balance between acyl-CoA formation and oxidation, and can be modulated by nutritional and pharmacological interventions.

Loss-of-function mutations in SLC22A5 cause primary carnitine deficiency, which impairs cellular carnitine uptake and leads to cardiomyopathy, muscle weakness, and hypoketotic hypoglycemia. Defects in CPT2 or SLC25A20 disrupt the mitochondrial acylcarnitine shuttle and cause severe fatty acid oxidation disorders with cardiac and hepatic manifestations. These conditions demonstrate that carnitine metabolic process is essential for normal energy homeostasis, and they are diagnosed by measuring carnitine and acylcarnitine species in blood.

Metabolomic profiling in psoriasis revealed significant alterations in amino acid and carnitine metabolites, suggesting that carnitine metabolic process is perturbed in inflammatory skin disease. In ischemic stroke, lipidomic analysis identified long-chain acylcarnitine as a potential target, indicating that carnitine derivatives contribute to or reflect ischemic brain injury. These findings support the use of carnitine-related metabolites as biomarkers and potential therapeutic targets in inflammatory and ischemic conditions.

In glioblastoma, inhibition of MET receptor tyrosine kinase elicits PGC1alpha-dependent metabolic reprogramming, which includes changes in mitochondrial oxidative metabolism. Because carnitine metabolic process supports fatty acid oxidation, cancer cells with altered mitochondrial function may depend on carnitine-dependent pathways for energy and survival. This makes carnitine metabolism a candidate target for metabolic therapy in cancers with specific driver mutations.

Carnitine is critical for muscle and heart bioenergetics because these tissues rely heavily on fatty acid oxidation for ATP production. Studies on myocardial carnitine transport have highlighted the importance of carnitine uptake for cardiac function. Carnitine supplementation has been investigated as a strategy to improve exercise performance and muscle recovery, although effects depend on baseline carnitine status and tissue uptake.

Mass spectrometry-based metabolomics and lipidomics are used to quantify free carnitine and acylcarnitine species in cells, plasma, and tissues. These methods have revealed carnitine alterations in psoriasis and identified long-chain acylcarnitine as a target in ischemic stroke. Targeted assays can measure specific acylcarnitines to assess fatty acid oxidation flux and diagnose inherited disorders.

CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of individual genes in carnitine metabolic process. For example, knocking out SLC22A5 can confirm its requirement for carnitine uptake, while knock-in of patient mutations can reproduce disease-associated defects. In cancer models, CRISPR editing of metabolic regulators such as PPARGC1A can reveal dependencies on carnitine-dependent pathways.

Extracellular flux analysis and mitochondrial respiration assays measure oxygen consumption and fatty acid oxidation capacity in live cells. These methods can determine whether genetic or pharmacological manipulation of carnitine metabolism alters mitochondrial energy production. They are often combined with acylcarnitine profiling to link genotype to metabolic phenotype.

RNA sequencing and proteomics can quantify expression of carnitine transporters and enzymes under different conditions, revealing regulatory mechanisms. In glioblastoma, MET inhibition induced PGC1alpha-dependent metabolic reprogramming that can be monitored by transcriptomic and proteomic changes. These approaches help identify upstream regulators of carnitine metabolic process.

Researchers studying carnitine metabolic process-related genes often need to determine whether a candidate gene is causally involved in carnitine transport, acylcarnitine formation, or fatty acid oxidation. EDITGENE provides CRISPR-based cell model services that enable precise knockout, point mutation, knock-in, and overexpression of genes such as SLC22A5, CPT1A, CPT2, and SLC25A20, allowing functional validation in relevant cell types.

Carnitine metabolic process (GO:0009437) is a central biological process that enables mitochondrial fatty acid oxidation and energy production. Its components, including SLC22A5, CPT1A, CPT2, and SLC25A20, are essential for carnitine transport and acylcarnitine shuttle, and their dysfunction causes severe metabolic disorders. Beyond inherited disease, carnitine and acylcarnitine profiles are altered in inflammatory and ischemic conditions and in cancer metabolic reprogramming. CRISPR-based functional genomics provides a powerful approach to dissect the causal roles of individual genes in carnitine metabolic process. By combining knockout, point mutation, knock-in, and overexpression models with metabolomics and mitochondrial assays, researchers can link genotype to metabolic phenotype and identify new therapeutic targets. EDITGENE supports these efforts with custom cell model generation and bioinformatics services tailored to carnitine metabolism research.